Navigation Links
Paclitaxel Plus Chemo Improves Outcomes in Early Breast Cancer
Date:5/27/2008

Study finds a trend toward better overall survival

TUESDAY, May 27 (HealthDay News) -- Adding paclitaxel to standard chemotherapy improved disease-free survival in women with early-stage breast cancer, a Spanish study finds.

The phase III trial included 1,246 women with early, non-metastatic breast cancer who were randomly assigned to receive treatment with fluorouracil, epirubicin, and cyclophosphamide (FEC), or FEC followed by weekly paclitaxel (FEC-P).

The estimated five-year survival rate in the FEC-P group was 78.5 percent, compared to 72.1 percent in the FEC group. The study also found a trend toward improved overall survival, but it didn't reach statistical significance.

"Because distant relapse-free survival is usually associated with overall survival, a statistically significant benefit in overall survival may become evident with a more protracted follow-up," wrote Dr. Miguel Martin, of the Spanish Breast Cancer Research Group.

In a retrospective analysis of the data, the researchers weren't able to identify a subgroup of patients who were more likely to respond to paclitaxel therapy on the basis of their tumor's expression of the estrogen receptor and HER2.

The study was published in the May 27 online issue of the Journal of the National Cancer Institute.

In an accompanying editorial, researchers at Memorial Sloan-Kettering Cancer Center in New York City reviewed several trials that examined the effects of adding taxanes (a family of drugs that include paclitaxel) to existing adjuvant therapy for breast cancer.

In that regard, the study by the Spanish team is important, because it was well-designed and used a good regimen and schedule of drugs, noted Dr. Clifford Hudis and Dr. Chau Dang.

More information

The National Cancer Institute has more about breast cancer treatment.



-- Robert Preidt



SOURCE: Journal of the National Cancer Institute, news release, May 27, 2008


'/>"/>
Copyright©2008 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. Analysis shows combining sorafenib with carboplatin/paclitaxel adds no benefit in lung cancer
2. Chemotherapy may be culprit for fatigue in breast cancer survivors
3. Replidyne Pipeline Featured at 47th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy
4. To evade chemotherapy, some cancer cells mimic stem cells
5. New chemotherapy regimen prolongs survival in difficult-to-treat childhood brainstem gliomas
6. PET scans can accurately detect a breast tumors response to chemotherapy
7. Chemotherapy with gemcitabine delays progression of operable pancreatic cancer
8. New Software Program Helps Breast Cancer Survivors and Patients Fight Chemofog
9. Medicare modernization act did not change chemotherapy as feared
10. HER-2 status predicts success of chemotherapy in breast cancer treatment, study finds
11. Cancer conflict with chemotherapy treatment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... ... February 24, 2017 , ... Congratulations to Head Over Heels’ ... February 12th. Ms. Esparza qualified into this prestigious status after winning the ... Las Vegas, Nevada. Frida is one of approximately 25 gymnasts in the nation ...
(Date:2/23/2017)... ... 23, 2017 , ... The 89th Academy Awards will be celebrated this weekend, ... Policy Center Bunkum Award. We invite you to enjoy our 11th annual tongue-in-cheek “salute” ... is the Center for American Progress (CAP), for its report, Lessons From State Performance ...
(Date:2/23/2017)... Los Angeles, CA (PRWEB) , ... February 23, 2017 , ... ... the first two episodes of WE TV’s “Mama June: From Not to Hot,” which ... of TV notable, “Mama” June Shannon, known to millions from the 2012 reality television ...
(Date:2/23/2017)... California (PRWEB) , ... February 23, 2017 , ... ... Sports Development will host a diverse symposium on “Doping in Sport: ... Law and Sheppard Mullin Richter & Hampton LLP. The symposium will be held ...
(Date:2/23/2017)... ... February 23, 2017 , ... ... that it will soon begin franchising throughout the U.S. starting this spring. Current ... bring the practice of meditation mainstream. Current Meditation will be the first meditation ...
Breaking Medicine News(10 mins):
(Date:2/24/2017)... YORK , Feb. 23, 2017  This report ... Thousand by the following Products: Intermediates, ... in the report include Pharmaceuticals, and Agrochemicals. The report ... Japan , Europe , and ... for the period 2015 through 2022. Also, a six-year ...
(Date:2/24/2017)... Research and Markets has announced the addition of the ... report to their offering. ... The latest research Urinary Incontinence Drugs Price Analysis and ... global Urinary Incontinence market. The research answers the following questions: ... for Urinary Incontinence and their clinical attributes? How are they positioned ...
(Date:2/23/2017)... MINNEAPOLIS , Feb. 23, 2017  Cogentix Medical, ... manufactures and markets innovative proprietary products for the urology ... and fiscal year ended December 31, 2016 before the ... The Company will host a conference call and ... on Thursday, March 9, 2017 at 11:00 a.m. Eastern ...
Breaking Medicine Technology: